---
title: "Dupixent (dupilumab) in atopic dermatitis: Access and coverage questions"
description: "Access and coverage questions on Dupixent (dupilumab) in atopic dermatitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Patient support, Access and support, and Prior authorization. Questions: Is injection training available for patients starting Dupixent? Is Dupixent covered by commercial insurance for atopic dermatitis? What affects how much Dupixent costs patients? Is there a Dupixent copay card? 11 further questions follow. 15 questions quoted from 9 sources."
canonical: "https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/access-and-coverage"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Dupixent (dupilumab) in atopic dermatitis: Access and coverage questions

Manufacturer: sanofi-aventis U.S. LLC; Regeneron Pharmaceuticals, Inc.  
Prescribing information: [Dupixent](https://www.regeneron.com/downloads/dupixent_fpi.pdf)

## Patient support

<a id="dupixent-injection-training"></a>

### Is injection training available for patients starting Dupixent?

> “Supplemental injection training is available with a DUPIXENT MyWay® Nurse Educator
>
> After initial training in your office, patients can receive supplemental injection training in person, online, or by phone. Patients can schedule a training by calling their DUPIXENT MyWay Case Manager.”

Source: [DUPIXENT: Injection Support, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/nursing-support#:~:text=Supplemental%20injection%20training%20is%20available,their%20DUPIXENT%20MyWay%20Case%20Manager.)

<a id="dupixent-myway"></a>

### What is the Dupixent MyWay patient support program?

> “DUPIXENT MyWay is a patient support program that offers insurance coverage support,
> financial assistance, and helpful resources for eligible patients who are prescribed DUPIXENT.”

Source: [DUPIXENT: DUPIXENT MyWay® Patient Support Program, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/dupixent-myway#:~:text=DUPIXENT%20MyWay%20is%20a%20patient,patients%20who%20are%20prescribed%20DUPIXENT.)

> “Your team includes:
>
> Field Reimbursement Manager: Providing you with education and support on DUPIXENT coverage and reimbursement
> Case Manager: Helping you keep track of patients' progress as they navigate access to DUPIXENT and DUPIXENT MyWay services
> Sales Professional: Providing you with clinical information regarding DUPIXENT and its FDA-approved indications”

Source: [DUPIXENT: DUPIXENT MyWay® Patient Support Program, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/dupixent-myway#:~:text=Your%20team%20includes%3A,DUPIXENT%20and%20its%20FDA%2Dapproved%20indications)

> “Call 1-844-DUPIXENT (1-844-387-4936) Option 1, Monday-Friday, 8 am-9 pm ET
> to speak with a DUPIXENT MyWay Case Manager.”

Source: [DUPIXENT: DUPIXENT MyWay® Patient Support Program, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/dupixent-myway#:~:text=Call%201%2D844%2DDUPIXENT%20%281%2D844%2D387%2D4936%29%20Option%201%2C,a%20DUPIXENT%20MyWay%20Case%20Manager.)

<a id="dupixent-myway-enrollment"></a>

### How do you enroll a patient in Dupixent MyWay?

> “Send the full enrollment form (pages 1-5) and insurance information via:
>
> Fax: 1-844-387-9370 
> Electronic upload: DUPIXENTMyWayPortal.com (use code: 8443879370)”

Source: [DUPIXENT: DUPIXENT MyWay® Enrollment, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/patient-enrollment#:~:text=Send%20the%20full%20enrollment%20form,upload%3A%20DUPIXENTMyWayPortal.com%20%28use%20code%3A%208443879370%29)

> “With the enrollment form, you can choose how DUPIXENT MyWay supports you and your patient with benefits investigation and prescription triage.
>
> If consent has not already been provided, DUPIXENT MyWay will contact your patient with a request to provide their consent to enroll in the program. Once consent is received, we will welcome them and share more details about the available support services.”

Source: [DUPIXENT: DUPIXENT MyWay® Enrollment, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/patient-enrollment#:~:text=With%20the%20enrollment%20form%2C%20you,about%20the%20available%20support%20services.)

## Access and support

<a id="dupixent-insurance-coverage"></a>

### Is Dupixent covered by commercial insurance for atopic dermatitis?

> “≈96% of commercial patients (6+ months of age) nationally are covered for DUPIXENT
> ≈89% of commercial patient lives have to fail only 1 or 2 prescription topical treatments
>
> <sup>a</sup>
> MMIT Analysis, May 2026. Analysis included DUPIXENT, tralokinumab, upadacitinib, abrocitinib, lebrikizumab, and nemolizumab.
>
> <sup>b</sup>
> Based on available published commercial UM coverage criteria.”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=%E2%89%8896%25%20of%20commercial%20patients%20%286%2B,published%20commercial%20UM%20coverage%20criteria.)

On the page, select: How likely are my patients to be covered for DUPIXENT?

Note: The Formulary Coverage page (dupixenthcp.com/atopicdermatitis/resources/formulary-coverage) cites an MMIT analysis from January 2026 and gives ≈86% for commercial patient lives that have to fail only 1 or 2 prescription topical treatments.

<a id="dupixent-cost"></a>

### What affects how much Dupixent costs patients?

> “The amount your patients pay for DUPIXENT will largely depend on whether they have insurance, the type of insurance they have, whether their insurance provider considers the medication to be preferred or not preferred, and whether they’ve met their deductible.”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=The%20amount%20your%20patients%20pay,whether%20they%E2%80%99ve%20met%20their%20deductible.)

On the page, select: How much does DUPIXENT cost?

Note: The captured Dupixent HCP pages state no list price.

<a id="dupixent-copay-card"></a>

### Is there a Dupixent copay card?

> “Eligible patients covered by commercial health insurance may pay as little as $0* in copay per fill of DUPIXENT through the DUPIXENT MyWay® Copay Card Program.”

Source: [DUPIXENT: Copay & Financial Assistance, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/copay-card#:~:text=Eligible%20patients%20covered%20by%20commercial,DUPIXENT%20MyWay%C2%AE%20Copay%20Card%20Program.)

> “Subject to the program maximum per patient per calendar year. Approval is not guaranteed. THIS IS NOT INSURANCE.”

Source: [DUPIXENT: Copay & Financial Assistance, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/copay-card#:~:text=Subject%20to%20the%20program%20maximum,guaranteed.%20THIS%20IS%20NOT%20INSURANCE.)

<a id="dupixent-copay-card-eligibility"></a>

### Who is eligible for the Dupixent copay card?

> “Patients may be eligible for the DUPIXENT MyWay Copay Card if they:
>
> Have commercial insurance, including health insurance exchanges, federal employee plans, or state employee plans
> Are a resident of any of the 50 United States, the District of Columbia, Puerto Rico, Guam, or the U.S. Virgin Islands  
> Are prescribed DUPIXENT for an indication approved by the FDA”

Source: [DUPIXENT: Copay & Financial Assistance, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/copay-card#:~:text=Patients%20may%20be%20eligible%20for,indication%20approved%20by%20the%20FDA)

> “Subject to the program maximum per patient per calendar year. Approval is not guaranteed. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs, including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed, or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients’ out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms. Additional terms and conditions apply.”

Source: [DUPIXENT: Copay & Financial Assistance, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/copay-card#:~:text=Subject%20to%20the%20program%20maximum,Additional%20terms%20and%20conditions%20apply.)

<a id="dupixent-copay-card-medicare"></a>

### Can Medicare patients use the Dupixent copay card?

> “Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs, including any state pharmaceutical assistance programs.”

Source: [DUPIXENT: Copay & Financial Assistance, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/copay-card#:~:text=Not%20valid%20for%20prescriptions%20paid%2C,any%20state%20pharmaceutical%20assistance%20programs.)

<a id="dupixent-patient-assistance"></a>

### Is there a Dupixent patient assistance program for uninsured or Medicare patients?

> “The DUPIXENT MyWay Patient Assistance Program can provide DUPIXENT at no cost to eligible patients, including those who are uninsured, underinsured, or have Medicare Part D.<sup>‡</sup>”

Source: [DUPIXENT: Copay & Financial Assistance, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/copay-card#:~:text=The%20DUPIXENT%20MyWay%20Patient%20Assistance,underinsured%2C%20or%20have%20Medicare%20Part)

> “Eligible commercial patients and Medicare patients without the Part D (pharmacy) benefit may receive free shipments of up to an 84-day supply of DUPIXENT (for up to 12 months). Patients may reapply after 12 months if they still meet the eligibility criteria. Patients with Medicare Part D who meet eligibility criteria must reapply for the Patient Assistance Program each calendar year, or by December 31st for eligibility consideration for the following year. The assistance period for Medicaid patients varies based on the eligibility criteria. Please note that DUPIXENT MyWay reserves the right to make eligibility determinations, monitor participation, ensure equitable product availability, and modify or discontinue the DUPIXENT MyWay Patient Assistance Program at any time without notice.”

Source: [DUPIXENT: Copay & Financial Assistance, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/copay-card#:~:text=Eligible%20commercial%20patients%20and%20Medicare,at%20any%20time%20without%20notice.)

<a id="dupixent-coverage-delay"></a>

### Can patients get Dupixent at no cost while waiting for insurance approval?

> “The Quick Start Program may temporarily provide DUPIXENT at no cost to eligible patients who are experiencing a delay in coverage.<sup>†</sup>”

Source: [DUPIXENT: Copay & Financial Assistance, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/copay-card#:~:text=The%20Quick%20Start%20Program%20may,are%20experiencing%20a%20delay%20in)

> “Patients may be eligible if they have a valid DUPIXENT prescription for an FDA-approved indication, are new to DUPIXENT, have prescription drug coverage for DUPIXENT through a commercial insurance plan not funded through a government healthcare program, are a resident of the United States, the District of Columbia, or Puerto Rico and treated by a licensed prescriber therein, are not an inpatient, are actively seeking coverage through their insurance provider, and are experiencing a coverage delay. Some patients may be subject to additional diagnostic criteria for eligibility.”

Source: [DUPIXENT: Copay & Financial Assistance, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/copay-card#:~:text=Patients%20may%20be%20eligible%20if,additional%20diagnostic%20criteria%20for%20eligibility.)

<a id="dupixent-coverage-gap"></a>

### Is there Dupixent support for patients with a gap in insurance coverage?

> “The DUPIXENT MyWay<sup>®</sup> Interim Access Program assists eligible, commercially insured patients who previously started DUPIXENT and are experiencing a specific, short-term lapse in therapy. It temporarily provides eligible patients DUPIXENT at no cost, subject to program terms and conditions.”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=in%20insurance%20coverage%3F-,The%20DUPIXENT,to%20program%20terms%20and%20conditions.)

On the page, select: Is support available for patients who have lost insurance or are changing jobs and will have a gap in insurance coverage?

<a id="dupixent-ndc"></a>

### What are the NDC codes for Dupixent?

> “The pre-filled syringe with needle shield is designed to deliver: 
> • 300 mg of DUPIXENT in 2 mL solution (NDC 0024-5914-00) 
> • 200 mg of DUPIXENT in 1.14 mL solution (NDC 0024-5918-00) 
> The pre-filled pen is designed to deliver: 
> • 300 mg of DUPIXENT in 2 mL solution (NDC 0024-5915-00) 
> • 200 mg of DUPIXENT in 1.14 mL solution (NDC 0024-5919-00) 
> DUPIXENT is available in cartons containing 2 pre-filled syringes with needle shield or 2 pre-
> filled pens.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 74, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=74)

> “Pack Size 
> 300 mg/2 mL (150 mg/mL) Pre-filled 
> Syringe with Needle Shield 
> 200 mg/1.14 mL (175 mg/mL) Pre-
> filled Syringe with Needle Shield 
> Pack of 2 syringes 
> NDC 0024-5914-01 
> NDC 0024-5918-01”

Source: [DUPIXENT: dupixent_fpi.pdf, page 75, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=75)

> “Pack Size 
> 300 mg/2 mL (150 mg/mL) Pre-filled 
> Pen 
> 200 mg/1.14 mL (175 mg/mL) Pre-
> filled Pen 
> Pack of 2 pens 
> NDC 0024-5915-02 
> NDC 0024-5919-02”

Source: [DUPIXENT: dupixent_fpi.pdf, page 75, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=75)

Note: The first passage gives the NDC of each single syringe or pen; the pack-size tables give the NDC of each carton of 2.

## Prior authorization

<a id="dupixent-prior-authorization"></a>

### What documentation does a Dupixent prior authorization for atopic dermatitis need?

> “A patient’s health plan is likely to require a prior authorization (PA) before it approves DUPIXENT for 
> appropriate patients. However you choose to submit a PA request (eg, fax, website, phone, CoverMyMeds<sup>®a</sup>), 
> this checklist can help guide you through the information health plans may need from you.”

Source: [DUPIXENT: Prior Authorization Checklist, page 1, captured 2026-11-12](https://www.dupixenthcp.com/dam/jcr:5d17302b-446a-4735-959f-751bc1653381/atopicdermatitis-dupixent-myway-prior-authorization-checklist.3ed4b52a5dbbfd78aa0350fe96e66312.pdf#page=1)

> “Ensure you document the following in the most recent chart notes: 
> • Patient’s diagnosis, using the appropriate ICD-10-CM code (eg, L20.__)  
> • Patient’s severity of atopic dermatitis (moderate or severe)
> • IGA score of 3 (moderate disease) or 4 (severe disease), if required  
> by payer
> • Patient’s current age and months/years since diagnosis
> • Percentage of body surface area affected (<10% or ≥10%)
> • Sensitive areas affected (eg, hands, feet, genitals/groin, scalp,  
> intertriginous areas, other)
> • Disease impact on patient’s health (eg, physical or other)
> • Current and prior therapies, documenting the treatment name, dose,   
> duration, and date of each therapy,<sup>a</sup> such as: 
> – Topical corticosteroids	
> – Topical PDE-4 inhibitor
> – Phototherapy”

Source: [DUPIXENT: Prior Authorization Checklist, page 2, captured 2026-11-12](https://www.dupixenthcp.com/dam/jcr:5d17302b-446a-4735-959f-751bc1653381/atopicdermatitis-dupixent-myway-prior-authorization-checklist.3ed4b52a5dbbfd78aa0350fe96e66312.pdf#page=2)

> “– Topical calcineurin inhibitors
> – Immunosuppressants 
> – Other”

Source: [DUPIXENT: Prior Authorization Checklist, page 2, captured 2026-11-12](https://www.dupixenthcp.com/dam/jcr:5d17302b-446a-4735-959f-751bc1653381/atopicdermatitis-dupixent-myway-prior-authorization-checklist.3ed4b52a5dbbfd78aa0350fe96e66312.pdf#page=2)

> “• Documentation of all prior therapies and/or if any recommended  
> therapies are considered inappropriate or contraindicated”

Source: [DUPIXENT: Prior Authorization Checklist, page 2, captured 2026-11-12](https://www.dupixenthcp.com/dam/jcr:5d17302b-446a-4735-959f-751bc1653381/atopicdermatitis-dupixent-myway-prior-authorization-checklist.3ed4b52a5dbbfd78aa0350fe96e66312.pdf#page=2)

> “Please keep in mind that PA requirements are likely to vary, so check with your patient’s health plan to ensure you 
> have an accurate list of requirements before you submit”

Source: [DUPIXENT: Prior Authorization Checklist, page 2, captured 2026-11-12](https://www.dupixenthcp.com/dam/jcr:5d17302b-446a-4735-959f-751bc1653381/atopicdermatitis-dupixent-myway-prior-authorization-checklist.3ed4b52a5dbbfd78aa0350fe96e66312.pdf#page=2)

> “We’re here to help you navigate the prior authorization and appeals process when needed. While prior authorizations are not initiated through DUPIXENT MyWay®, we provide tailored checklists, guides, and sample letters to support you every step of the way.”

Source: [DUPIXENT: Insurance Coverage Support, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/coverage-support#:~:text=We%E2%80%99re%20here%20to%20help%20you,every%20step%20of%20the%20way.)

> “DUPIXENT MyWay works with CoverMyMeds® to provide simple, fast ePA
> support.”

Source: [DUPIXENT: Insurance Coverage Support, captured 2026-11-12](https://www.dupixenthcp.com/patient-support/coverage-support#:~:text=DUPIXENT%20MyWay%20works%20with%20CoverMyMeds%C2%AE,support.)

<a id="dupixent-pa-denials"></a>

### Why are Dupixent prior authorization requests denied?

> “Incomplete information may lead to a denial for DUPIXENT<sup>®</sup> (dupilumab) 
> Below are some of the most common causes for denial. It is important that you double check your 
> documentation when you submit your initial PA request to avoid these common causes for denial.
> Common reasons for coverage denials
> •	 Documentation did not support health plan’s criteria 
> for approval of DUPIXENT
> •	 Patient was not treated with prior therapies required  
> by plan
> •	 No reason provided for discontinuation of previous 
> therapy/therapies
> •	 Clerical error (ie, missing or incorrect ICD-10-CM code)
> •	 Lack of documentation supporting appropriate 
> diagnosis or other required documentation from most 
> recent chart notes
> – Consider indicating on your PA form the page on which the 
> supporting clinical data can be found
> •	 Did not include duration on current therapies or names of 
> all therapies that were tried and failed”

Source: [DUPIXENT: Prior Authorization Checklist, page 3, captured 2026-11-12](https://www.dupixenthcp.com/dam/jcr:5d17302b-446a-4735-959f-751bc1653381/atopicdermatitis-dupixent-myway-prior-authorization-checklist.3ed4b52a5dbbfd78aa0350fe96e66312.pdf#page=3)

<a id="dupixent-pa-appeal"></a>

### How do you appeal a denied Dupixent prior authorization for atopic dermatitis?

> “If your patient’s PA is denied, you can appeal the decision. A successful appeal may include the following 
> checklist of information, compiled in an appeal packet.”

Source: [DUPIXENT: Prior Authorization and Appeals Guide, page 5, captured 2026-11-12](https://www.dupixenthcp.com/dam/jcr:2e300e61-3352-4128-9730-41bdb195ae5d/atopicdermatitis-dupixent-myway-appeals-guide.fbf6491c72d2ec1033281d0f6e307397.pdf#page=5)

> “A letter of appeal signed by the treating physician and patient or caregiver, if required.”

Source: [DUPIXENT: Prior Authorization and Appeals Guide, page 5, captured 2026-11-12](https://www.dupixenthcp.com/dam/jcr:2e300e61-3352-4128-9730-41bdb195ae5d/atopicdermatitis-dupixent-myway-appeals-guide.fbf6491c72d2ec1033281d0f6e307397.pdf#page=5)

> “Appeal letters can 
> be customized depending on the reason a PA has been denied.”

Source: [DUPIXENT: Prior Authorization and Appeals Guide, page 5, captured 2026-11-12](https://www.dupixenthcp.com/dam/jcr:2e300e61-3352-4128-9730-41bdb195ae5d/atopicdermatitis-dupixent-myway-appeals-guide.fbf6491c72d2ec1033281d0f6e307397.pdf#page=5)

> “The appeal form recommended by the health plan
> In addition to the letter of appeal and appeal form, consider including current and/or recent chart notes 
> from the patient’s treating physician to make the appeal as thorough as possible, including:
> Date of initial diagnosis
> Severity and frequency of flares  
> BSA involved with body location (eg, hands, feet, face and neck, genitals/groin, scalp,  
> or intertriginous areas)
> Response to all prior therapies (eg, name of therapy, dose, start date/stop date, length of treatment,  
> and clinical response)
> Any relevant comorbidities or contraindications 
> If appropriate, earlier treatment history from previous physicians, provided by the patient 
> Recent photos of the patient’s condition. Include treatment regimen when photos were taken
> International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code matching 
> your patient’s diagnosis
> Reasons why the patient’s recent symptoms, severity of condition, and impact of disease  warrant 
> treatment with DUPIXENT<sup>®</sup> (dupilumab) 
> Any clinical studies<sup>a</sup> or peer reviewed articles documenting the medical effectiveness of DUPIXENT 
> DUPIXENT full Prescribing Information, available at www.DUPIXENThcp.com
> A personal narrative from the patient that describes the impact of their condition”

Source: [DUPIXENT: Prior Authorization and Appeals Guide, page 5, captured 2026-11-12](https://www.dupixenthcp.com/dam/jcr:2e300e61-3352-4128-9730-41bdb195ae5d/atopicdermatitis-dupixent-myway-appeals-guide.fbf6491c72d2ec1033281d0f6e307397.pdf#page=5)

> “Key points to consider when filing an appeal on behalf of your patient:
> •	
> Adhere to the timelines and use the forms noted in the health plan’s letter of denial
> •	
> Depending on the health plan, your patient’s signature may be required on the appeal letter (if patient 
> is a minor, a guardian’s signature is required)
> •	
> The appeal packet should be submitted by your office or your patient
> •	
> Two levels of internal review may be required before the health plan will notify you of your patient’s 
> eligibility for an external appeal. If this occurs, the reviewer will be an independent party, typically 
> board certified in the specialty. Their decision will be binding on the health plan
> –    All documentation from previous reviews should be submitted in subsequent appeals
> Remember, successful appeals may take more than 1 attempt.<sup>1</sup> Patients can also advocate for an appeal on 
> their own behalf, and HCPs may request a peer-to-peer review with a medical reviewer at a health plan.
> DUPIXENT MyWay<sup>®</sup> can help educate your office about the appropriate actions needed to appeal a coverage denial.  
> DUPIXENT MyWay Appeal Specialists can help provide support throughout the appeal process.”

Source: [DUPIXENT: Prior Authorization and Appeals Guide, page 6, captured 2026-11-12](https://www.dupixenthcp.com/dam/jcr:2e300e61-3352-4128-9730-41bdb195ae5d/atopicdermatitis-dupixent-myway-appeals-guide.fbf6491c72d2ec1033281d0f6e307397.pdf#page=6)

## Related pages
- [Medical information: Dupixent (dupilumab): Atopic dermatitis](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis)
- [Indication](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/guidelines)
